Uzun Süreli Valproik Asit ve Karbamazepin Tedavisinin Vücut Kitle İndeksi ve Serum Lipid Düzeyi Üzerine Etkisi

Denız, Orhan; Keklikoğlu, Dönmez Hava; Keskin, Selda; Vural, Gönül

doi:10.4274/npa.y5982

Cited by 1 publication

(1 citation statement)

References 16 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study conducted by Deniz et al in 2011, LDL-cholesterol levels were found to be significantly higher, whereas no difference was observed in HDL-cholesterol levels (11).…”

Section: Discussionmentioning

confidence: 90%

Karbamazepin Kullanan Hastalarda Serum Lipid Düzeylerinin Değerlendirilmesi

GÜRCÜ,

UNCU,

UNCU

2023

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

Epilepsy is a neurological disease that requires long-term drug therapy. Carbamazepine (CBZ) is a drug that is effective in partial seizures, including complex partial seizures, and tonic-clonic seizures. It was aimed to evaluate the effect on serum lipid profile in patients who used CBZ. Medical biochemistry laboratory data between January and December 2021 were analyzed retrospectively. Patients (n=59) who used monotherapy and at least 2 years of CBZ were included in the study. Patients under 18 years of age were not included. In the control group, 34 healthy people with normal blood parameters, who applied to outpatient clinics for different reasons at the same age, and did not have a disease that would affect the lipid profile, were selected. The mean age of the patients was 36 ±8 years. LDL-cholesterol levels were found to be higher in patients treated with carbamazepine compared to the control group (p<0.05). There was no significant difference in serum triglyceride (TG), and HDL-cholesterol levels in the patient and control groups (p>0.05). There was no gender difference in the effect of carbamazepine on LDL-cholesterol (p>0.05). High serum LDL-cholesterol levels cause atherosclerosis and coronary artery disease. The lipid profile of carbamazepine, which is used regularly at the therapeutic level, changes. Due to the association of high LDL-cholesterol levels with atherosclerosis, it is important to monitor lipid levels in patients using CBZ, especially considering the long duration of use of this pharmacotherapy.

show abstract

“…In a study conducted by Deniz et al in 2011, LDL-cholesterol levels were found to be significantly higher, whereas no difference was observed in HDL-cholesterol levels (11).…”

Section: Discussionmentioning

confidence: 90%